
Allarity Therapeutics, Inc.
ALLRHealthcare|Biotechnology|US
$0.96
-0.01 (-1.13%)
DCF Value
$1.18
Tangible Book / Share
$0.22
Cash / Share
$1.07
Next Earnings Report
Nov 13, 2026
EPS est. -$0.21
Financing Filings (last 12 months)
6
Shelf registrations / offering prospectuses — latest Oct 30, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (2)
Mar 2027
Est. completion
P2Advanced Ovarian Cancer
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
NCT03878849n=40
Jun 2027
Est. completion
Recent Press Releases
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
Oct 30, 2026 · GlobeNewsWire
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development
Sep 30, 2026 · GlobeNewsWire
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Sep 28, 2026 · GlobeNewsWire
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
Sep 15, 2026 · GlobeNewsWire
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
Sep 11, 2026 · GlobeNewsWire
SEC Filings (79)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 2, 2026 | 8-K | Material event | DocumentIndex |
| Oct 30, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Oct 30, 2026 | 8-K | Material event | DocumentIndex |
| Oct 1, 2026 | 8-K | Material event | DocumentIndex |
| Sep 29, 2026 | 8-K | Material event | DocumentIndex |
| Sep 16, 2026 | 8-K | Material event | DocumentIndex |
| Sep 14, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 1, 2026 | 8-K | Material event | DocumentIndex |
| Jun 22, 2026 | 8-K | Material event | DocumentIndex |
| Jun 2, 2026 | 8-K | Material event | DocumentIndex |
| May 15, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 8, 2026 | 8-K | Material event | DocumentIndex |
| May 6, 2026 | 8-K | Material event | DocumentIndex |
| Apr 30, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 30, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 30, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 28, 2026 | 8-K | Material event | DocumentIndex |
| Apr 27, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| Apr 24, 2026 | EFFECT | DocumentIndex | |
| Apr 24, 2026 | S-3/A | Shelf registration | DocumentIndex |
| Apr 22, 2026 | 8-K | Material event | DocumentIndex |
| Apr 10, 2026 | PRE 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 1, 2026 | 8-K | Material event | DocumentIndex |
| Mar 30, 2026 | 10-K | Annual report | DocumentIndex |
| Mar 9, 2026 | 8-K | Material event | DocumentIndex |
| Mar 6, 2026 | 8-K | Material event | DocumentIndex |
| Feb 19, 2026 | 8-K | Material event | DocumentIndex |
| Feb 12, 2026 | S-3 | Shelf registration | DocumentIndex |
| Feb 4, 2026 | 8-K | Material event | DocumentIndex |
| Jan 29, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jan 29, 2026 | 8-K | Material event | DocumentIndex |
| Dec 23, 2025 | 8-K | Material event | DocumentIndex |
| Dec 8, 2025 | 8-K | Material event | DocumentIndex |
| Dec 5, 2025 | EFFECT | DocumentIndex | |
| Dec 3, 2025 | S-3 | Shelf registration | DocumentIndex |
| Nov 14, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Sep 30, 2025 | EFFECT | DocumentIndex | |
| Sep 30, 2025 | 424B3 | Offering prospectus | DocumentIndex |